RxDoctor Payments Data

Victor Hartanto, MD

Urology · Midland Park, NJNPI 1376679639

Payments from drug & device makers

$1,038in general payments, 2019–2025

Across 22 payments — averaging $47.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Profound Medical Corp.$156
  • Immunitybio, Inc.$154
  • Procept Biorobotics Corporation$150
  • Sumitomo Pharma America, Inc.$108
  • Axonics, Inc.$107
  • Pfizer$96
  • plus $268 from 7 others

What the payments were for

  • Food & beverage$85382%
  • Education$18418%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Profound Medical Corp.1$156
Immunitybio, Inc.1$154
Procept Biorobotics Corporation1$150
Sumitomo Pharma America, Inc.1$108
Axonics, Inc.1$107
Pfizer7$96
Astellas Pharma US Inc1$88
Calyxo, Inc.2$49
Olympus America Inc.2$38
Boston Scientific2$35
Civco Medical Instruments1$21
C. R. Bard, Inc. & Subsidiaries1$19
AstraZeneca1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,038 in reported general payments places this provider in the 30th percentile of 401 urology providers in New Jersey.

See all urology providers in New Jersey

Medicare billing

Part B allowed, 2024
$956,253
Medicare patients
1,428
Services billed
18,077

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron812$694,663
GemtesaVibegron361$336,235
Silodosin452$50,246
Estradiol402$38,242
Mirabegron ErMirabegron41$26,955
PremarinEstrogens, Conjugated44$18,747
Tamsulosin Hcl727$17,151
CefuroximeCefuroxime Axetil455$8,801
YuvafemEstradiol42$8,359
XareltoRivaroxaban13$7,134
Bethanechol Chloride50$5,649
Methenamine Hippurate65$3,832
Desmopressin Acetate41$3,756
Finasteride161$2,989
Fesoterodine Fumarate ErFesoterodine Fumarate18$2,824

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$88$694,663812 claims
Sumitomo Pharma America, Inc.Gemtesa$108$336,235361 claims
PfizerPremarin$96$18,74744 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 401 urology providers in New Jersey.

Other urology in Midland Park

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →